2-sample fecal test less effective than 1-sample — 4 insights

A study published in The Lancet Gastroenterology & Hepatology found that two-sample fecal immunochemical tests did not significantly improve detection rates over one-sample FIT.

Researchers put subjects through four rounds of either 1-FIT or 2-FIT screening between 2006 and 2015. About 7,310 1-FIT participants completed at least one round of screening, and 2,269 2-FIT participants completed at least one round of screening.

What they found:

1. The 1-FIT cohort had a 19.2 percent cumulative positive rate, lower than the 28.5 percent rate the 2-FIT cohort posted.

2. Cumulative positive predictive value was higher in the 1-FIT cohort (33 percent) than the 2-FIT cohort (24.2 percent).

3. Diagnostic yield of advanced neoplasia was higher in the 2-FIT cohort (4.7 percent) than the 1-FIT cohort (4.4 percent).

4. Eight people in the 1-FIT cohort and two people in the 2-FIT cohort had interval colorectal cancers.

Researchers said one-sample FIT programs were preferred to two-sample FIT programs because, "Four rounds of 2-FIT screening with a low faecal haemoglobin cutoff level did not result in a significant increase in diagnostic yield or a decrease in interval colorectal cancers compared with 1-FIT, despite higher colonoscopy demand."

More articles on gastroenterology:
3 states considering ASC-related reforms
9 financial benchmarks for ASCs to track
Consolidation, new technologies & more: top 4 challenges ASCs face in the outpatient market

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers